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Abstract
Background: Angiogenesis is critical to tumor growth and is therefore a potential target for cancer therapy. As
many current inhibitors of angiogenesis exhibit host toxicity, natural alternatives are needed. At millimolar
concentrations, ascorbate (vitamin C) inhibits migration and tubule formation by mature endothelial cells and
endothelial progenitors. In the present study, we examined the effects of ascorbate, at levels relevant during
intravenous infusion therapy, on angiogenesis using an ex vivo an in vivo assay.
Methods: Two assays were used to evaluate effect of high-doses ascorbic acid on angiogenesis: ex vivo rat aortic
ring explant assay in Matrigel matrices and in vivo Matrigel plug assay. In aortic rings, we quantified microvessel
growth, branching and vessel regression under different treatment conditions. In murine angiogenesis assay, male
C57 mice 6-8 weeks old were treated by high-dose ascorbic acid and the number of microvessels was analyzed by
histological method. To characterize the population of cells that formed capillary network and microvessels, the
sections were stained by CD34 and CD31 antibodies.
Results: Results show that sprouting of endothelial tubules from aortic rings was reduced in a concentration-
dependent fashion by ascorbate: while controls roughly tripled sprout densities during the study, ascorbate (1 mg/
mL, 5.5 mM) actually reduced sprout density. In vivo, the ability of mice to vascularize subcutaneously implanted
Matrigel plug was diminished if the mice were treated with 430 mg/kg vitamin C: numbers of vessels, and vessel
densities, in plugs from treated mice were roughly 30% less than those in plugs from untreated mice.
Conclusions: We conclude that the inhibition of angiogenesis by ascorbate suggested in vitro is confirmed in vivo,
and that angiogenesis inhibition may be one mechanism by which intravenous ascorbate therapy shows efficacy
in animal experiments and clinical case studies.
Background
Angiogenesis, the generation of new blood vessels, is
thought to be necessary for tumor growth and metasta-
sis [1-5]. Thus, there is considerable interest in develop-
ing anti-cancer therapies based on the inhibition of
tumor-induced angiogenesis [6,7]. Most angiogenesis
inhibitors currently being tested work either by neutra-
lizing endothelial cell growth factors, inhibition endothe-
lial cell proliferation, preventing turnover of basement
membrane, or blocking capillary formation. Unfortu-
nately, most of these agents are toxic and have high risk
of adverse effects. In hopes of finding less toxic
angiogenesis inhibitors, substances derived from natural
sources, such as flavonoids, sulphated carbohydrates, or
triterpenoids are being examined, as are natural health
products such as herbs, phytochemicals, and antioxi-
dants [8,9].
In regard to antioxidant angiogenesis inhibitors, vita-
min C is of particular interest for a variety of reasons.
First, it is has already been shown to have anti-tumor
effects in certain experimental and clinical settings, pro-
vided that ascorbate concentrations reach the millimolar
range [10-15]. Secondly, its role in supporting the later
stages of wound healing, particularly collagen formation
and strengthening of extracellular matrix, may counter
tumor-induced neovascularization [10]. Moreover, its
antioxidant activity may regulate some aspects of
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any medium, provided the original work is properly cited.endothelial cell migration, since some aspects of this are
promoted by nitric oxide and other oxidants [16].
In a recent study, sodium ascorbate at millimolar con-
centrations was shown to inhibit tubule formation by
endothelial cells on Matrigel, endothelial cell prolifera-
tion (but not viability), endothelial cell migration, and
reduce nitric oxide concentrations (NO is a major sti-
mulator of angiogenesis). These observations held for
both mature endothelial cells and endothelial progenitor
cells [16].
The previous work is limited to study of in vitro mod-
els. This typically raises two questions: do the observa-
tions extend to a more physiological model system, and
are the pharmacokinetics of vitamin C such that suffi-
cient levels can be attained in situ to reproduce in vitro
effects. The goal of the present manuscript is to test the
hypothesis that ascorbate, delivered by injection at doses
designed to attain millimolar plasma concentrations, will
inhibit neovascularization in vivo. To study a more phy-
siological model (using tissue sections rather than cell
lines), we examined the effect of ascorbate on outgrowth
of microvessels from rat aorta rings. To address the var-
ious issues associated with in vivo application, we exam-
ined the effect of ascorbate injections on the growth of
new blood vessels into Matrigel plugs implanted into
mice. This latter model provides an excellent test of in




Rat aortic ring explant cultures were prepared by modi-
fication of protocols previously described [17-21]. 24
well plates were covered by 150 ul of Matrigel (Becton
Dickenson, Bedford, MA). Aortic rings were prepared
from male Sprague Dawley rats. Aortas were sectioned
into 1 mm-long cross sections, rinsed several times with
endothelial growth medium M-200 (Cascade Biologics),
placed on Matrigel in wells and covered with an addi-
tional 50 ul of Matrigel. The rings were cultured in 1 ml
of endothelial medium for several days. Cultures were
incubated at 37C, in humidified CO2 and the medium
was replaced daily. As microvessels began to branch and
develop, some wells with aortic rings were kept as con-
trol and other wells were treated with sodium ascorbic
acid. Analysis of the macrovessel growth was performed
by counting number of pixels by NIH Image software
program (NIH, Bethesda, MD) [22].
Matrigel plug assay
In vivo angiogenesis measurements using Matrigel plugs
were performed as previously described [23,24]. Normal
male mice (C57BL/6) 6-8 weeks of age and weighing
~20 g were obtained from Charles River Laboratory and
allowed to acclimate for 3-4 days prior to the start of
treatments. C57Bl/6 mice were used as a host, since the
EHB tumor (i.e. Endelbreth-Holm-Swarm sarcoma)
from which Matrigel is derived, is propagated in these
mice and therefore does not elicit an immune response
and does not require the use of athymic mice. The
study was approved by the Institutional Review Board
and was conducted in accordance with the Declaration
of Helsinki and the Office of Laboratory Animal Welfare
regulation. Aliquots of Matrigel with growth factors
(FGF and VEGF) were prepared on ice. Final concentra-
tions of growth factors used in all experiments were 50
ng/ml FGF and 100 ng/ml VEGF. Matrigel (0.8 mL) was
injected into the ventral side of mouse, as it is the best
area in terms of angiogenic response. Matrigel was
allowed to gel for about 10 sec before removing needle
at the end of injection.
Sodium ascorbate was administered every other day
for a period of two weeks, the alternate day cycle being
consistent with how intravenous vitamin C is used clini-
cally at our facility [14,15]. Fresh sodium ascorbic acid
solution was prepared every other day, and a dosage of
8.6 mg per mouse (430 mg/kg for a 20 gram mouse)
was used (in clinical studies with humans, this dosage
was sufficient to give plasma ascorbate concentrations in
the millimolar range). We found in preliminary studies
that two weeks was a sufficient time period to allow
measurable neovascularization of the implanted Matrigel
plug. After two weeks of treatment, mice were eutha-
nized by CO2 asphyxiation for plug exclusion. Matrigel
plugs were removed two weeks after implantation and
were fixed in 10% neutral buffered formalin prior to
paraffin processing. These experiments have been repro-
duced three times.
The angiogenic activity was analyzed by immunohisto-
chemical staining and staining by hematoxylin and eosin.
Total number of microvessels containing red blood cells
and number of capillaries in a high power field (400× mag-
nifications) were counted. Vessel count and size was deter-
mined using ProgRes Capture Pro software.
To further analyze these microvessels, some sections
were stained with antibodies to CD34 (rabbit polyclonal,
Abcam) and CD31 (1:200, goat poly-IgG, Santa Cruz).
Antibodies were detected using 1% hydrogen peroxide fol-
lowed by avidin-biotin complex (ABC kit, Vector Labora-
tories) and visualized with diaminobenzidine (DAB).
Statistical analysis
For comparison of microvessel densities and capillary
densities for treated and non-treated groups, statistical
analysis was carried out by Mann-Whitney U test. P
values less than 0.05 were considered significant.
Results
The outgrowths of endothelial tubules from aorta rings
are shown in Figure 1. Panels A and C show untreated
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obvious expansion of tubules, presumably a combination
of endothelial cells, mesenchymal cells, and perivascular
cells [25-27]. In contrast, this expansion was suppressed
by incubation in 1 mg/mL (5 mM) ascorbic acid: Panels
B and D show ascorbate treated rings at days 0 and 4,
respectively. As a further check, we analyzed the sprout-
ing using the higher magnification and found that there
was additional vessel development from aortic intimal/
subintimal layers. Thus, angiogenesis as observed in our
analysis was due to new vessel formation and not just
sprouting from the initial vessels. By starting treatment
when we saw initial vessel development, we excluded
samples, in which vessel development was inhibited for
other reasons.
Figure 2 shows the effect of ascorbate on the percen-
tage of total area in the field of view occupied by
tubules. Outgrowth area (percent total) as a function of
time and of dosage (inset, after 5 days of treatment) is
shown. Ascorbate was administered starting on day
three at a concentration of 1 mg/dL (5 mM). The inset
shows ratios of microvessel areas before and after
treatment for five days rings exposed with various levels
of ascorbate. While the growth of endothelial microves-
sels from the aorta continues steadily in controls, new
formations stop forming by day two in ascorbate treated
samples. As shown in the bar graph inset, there is a
dose-response effect, with higher levels of ascorbate
leading to reduced outgrowth of vascular shoots. The
levels of vitamin C used here are consistent with those
used in plasma during ascorbate injection therapy
[28,29]. Hence, the inhibition of angiogenesis seen here
is occurring under conditions that may be relevant dur-
ing treatment.
Histological sections of Matrigel plugs were examined.
The hematoxylin/eosin stains of cross sections of the
plugs demonstrated that injection of Matrigel with
VEGF and bFGF to the mice induced cellularity, the for-
mation of tubules and many blood-filled channels con-
taining red blood cells. We saw both large vessels,
presumably the result of preexisting vessels extending
into the Matrigel, and microvessels and capillaries that
may be examples of angiogenesis and neovascularization.
To characterize the population of cells that formed
Figure 1 Developing microvessels from the intimal/subintimal layers of the aortic wall. A, B-microvessel outgrowth at the beginning of
experiments, C-non-treated well, D-well treated by 1 mg/mL ascorbic acid during 4 days.
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stained by markers that demonstrated the endothelial
type of cells. Matrigel plugs were stained antibodies to
CD34 and CD31; positive cells are seen in both cases,
demonstrating that the vessels formed within these
plugs are endothelial cell origin.
The effect of vitamin C on vascularization in Matrigel
plugs in vivo can be quantified by counting total num-
bers of microvessels using 200× magnification. Results
are shown in Figure 3. The decrease in microvessel for-
mation concurrent with ascorbate therapy (70 ± 25 for
control and 49 ± 20 for treated mice) and is statistically
significant (one-sided p-value < 0.05). This was verified
by capillary density measurements using image software:
Matrigel plugs from control mice showed capillary
densities of 30% ± 6%, while those from ascorbate trea-
ted mice showed capillary densities of 22% ± 5%. In
short, subcutaneous injections of Matrigel in mice
induce plugs containing new vessels, comprised in part
of endothelial and progenitor cells. This neovasculariza-
tion is diminished in mice treated with ascorbate at
doses used in clinical studies with intravenous infusions.
Discussion
The results detailed above, along with those in our pre-
vious publication, suggest that ascorbate has an inhibi-
tory effect on angiogenesis and neovascularization at
concentrations relevant to those attained in intravenous
ascorbate therapy. Our previous in vitro studies [16]
showed that ascorbate inhibited several aspects of
Figure 2 The effect of ascorbic acid on microvessel growth in aortic ring assay. Microvessel outgrowths (percentage of area occupied by
vessels) for controls and treated aorta rings as a function of time. Ascorbate was administered starting on day 3 at a concentration of 1 mg/dL
(5 mM) (lines represent second order polynomial fits via Kaleidograph). The inset shows ratios of microvessel areas before and after treatment for
five days rings exposed with various levels of ascorbate.
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tion on Matrigel, migration to fill gaps on monolayer,
and endothelial cell proliferation); moreover, these
effects were more pronounced on new vessel formation
than on existing vessels.
Experiments in aortic rings allowed examination of
ascorbate effects under conditions where endothelial
cells, progenitor cells, and other micro environmental
factors are interacting. Vitamin C is likely to regulate, or
impact, several processes of various cell types present.
The overall effect, however, is inhibitory. The Matrigel
plug assay allowed us to examine ascorbate in an in vivo
environment. This is important not only because of the
complexities involved in neovascularization in situ, but
also because of concerns about ascorbate pharmacoki-
netics. In these studies, ascorbate clearly had an inhibi-
tory effect, suggesting that it was distributed to these
tissues in sufficient quantities to act. One complication
to interpretation of these results is that mice are able to
produce their own vitamin C, an ability not shared by
humans. Ascorbate levels were not measured in our
Matrigel plugs, so we do not know what the actual con-
centrations were at the angiogenesis site. It is possible
that neovascularization in control mice was less than it
could have been because the mice produced extra ascor-
bate in response to the stress of participating in the
study.
The mechanism of action by which vitamin C may
inhibit neovascularization is still subject to speculation.
Earlier work suggests that ascorbate may act by reducing
nitric oxide levels; as NO is an important regulator of
angiogenesis [16]. Ascorbate may inhibit angiogenesis as
an antioxidant by suppressing angiogenesis stimulated
by reactive oxygen species [30]. For example, the
scavenging of peroxynitrite reduces vascular permeabil-
ity in tumor [31].
In the situation of tumor angiogenesis, vitamin C may
possibly have other beneficial effects. The inhibitory
effect of ascorbate in tube formation is involved in the
preferentially enhanced type I and III collagen synthesis
[32]. Ascorbate can have direct cytotoxicity against
tumor cells (which in turn would reduce the production
of pro-angiogenesis cytokines) in some instances [13,14],
and/or it can inhibit the expression of angiogenesis-
related genes [33]. This assertion is supported by recent
research indicating that tumor-bearing animals treated
with ascorbate survive longer than untreated controls,
due to the later forming highly invasive tumors that are
not observed in treated animals [34].
Ascorbate may also influence angiogenesis through its
effects on hypoxia-inducible factor (HIF). HIF is thought
to be important in regulating tumor progression and
angiogenesis [35-37]. Ascorbate has been shown to
diminish HIF levels [38] and inhibit the enhancement of
HIF by glucose metabolites [35]. In fact, Gao et al. have
indicated that the ability of ascorbate (and other antioxi-
dants) to inhibit tumor formation relates to its effects
on HIF, not to its protection of DNA [38].
As more animal studies and clinical trials are con-
ducted with intravenous ascorbate therapy, the evidence
of angiogenesis inhibition should be considered when
assessing the results of these studies. Also, this work
supports the utility of examining natural products and
vitamins for potential angiogenesis regulatory activity.
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